多项指标联合评价表阿霉素心脏毒性的临床研究

Multiple-factor evaluation of the cardiac toxicity of epirubicin

目的 :探讨表阿霉素心脏毒性的临床量化指标。方法 :对60例含表阿霉素化疗的恶性肿瘤病人采用化疗前、化疗中、化疗后监测心电图、心肌酶和超声心动的方法分析表阿霉素在正常心脏和异常心脏的耐量情况。结果 :心脏毒性组与正常对照组的心脏毒性和累积有显著性不同。结论 :表阿霉素用量与心脏状况密切相关 ;心脏病人的表阿霉素用量不宜超过600mg/m2 ,同时应适当加用心脏保护剂。

Objective:To study the clinical limited accumulation of epirubicin.Methods:A controlled study of60malignant tumor cases on ECG,myocardial enzyme and left ventricular ejection fraction in the chemotherapy was carried out.Results:The occurrance rate of cardiac toxicity and limited accumulatation were significant different between cardiopathy group and normal group.Conclusion:The limited accumulation of epirubicin is associated with cardiac function and should not more than600mg/m 2 when it can be used in the malignant tumor with cardiopathy.